ライフサイエンスコーパス: specific antigen

1 A PET-derived parameters with serum prostate-specific antigen.

2 c response among KD patients and controls to specific antigen.

3 t are associated with pre-operative prostate-specific antigen.

4 ed with different concentrations of prostate specific antigen.

5 S) for real-time and label-free detection of specific antigen.

6 ineered dendritic cells (tolDCs) loaded with specific antigens.

7 ogeneity since antibodies can only recognize specific antigens.

8 ood, which suggests that they may experience specific antigens.

9 r T cells become activated against recipient-specific antigens.

10 stimulated with both unspecific and pathogen-specific antigens.

11 ic antigen < 10 ng/mL or Gleason 6, prostate-specific antigen, 10 to 20 ng/mL), LDR brachytherapy alo

12 % N0M0; 94% newly diagnosed; median prostate-specific antigen, 66 ng/mL.

13 y correlated with the expression of prostate-specific antigen, a marker of AR signaling.

14 t host T cells properly primed against tumor-specific antigens after conventional treatment, which ca

15 gh affinity and specificity of mAb for tumor-specific antigens allow these vesicular antibodies (VAs)

16 ove specificity over measurement of prostate-specific antigen alone for detecting cancer with Gleason

17 The focus of tumour-specific antigen analyses has been on single nucleotide

18 adjusting for age and longitudinal prostate-specific antigen and digital rectal examination.

19 ydroxyvitamin D) and 2 nonhormones (prostate-specific antigen and ferritin).

20 Serology assays can detect EBOV-specific antigens and antibodies cost-effectively withou

21 ndicates CD4(+) T cells can recognize cancer-specific antigens and control tumor growth.

22 d with the singlet oxygen in the presence of specific antigens and emitted anti-Stokes fluorescence w

23 ndings highlight an important class of tumor-specific antigens and have implications for targeting ge

24 d from them, it is possible to image disease-specific antigens and immune cell subsets.

25 Mtb- specific antigens and live bacillus Calmette-Guerin (BCG

26 umors is hampered by the lack of truly tumor-specific antigens and poor control over T cell activity.

27 is relevant for most MCL cases, although the specific antigens and the precise location of affinity m

28 thod to rapidly discover conserved, pathogen-specific antigens and their epitopes, and applied it to

29 significant decrease in both KLK3 (prostate-specific antigen ) and FOLH1 (prostate-specific membrane

30 nalysis, controlling for age, serum prostate specific antigen, and abnormal digital rectal examinatio

31 nce status, higher testosterone and prostate-specific antigen, and lower hemoglobin than white men.

32 ression-free survival (PFS); tumor, prostate-specific antigen, and pain response; pharmacokinetics; a

33 by the pathogen, host antibody responses to specific antigens, and peripheral lymphocyte population

34 The adsorbed antigens through specific antigen-antibody binding interactions induced a

35 ity of pCB-(DOPA)4-modified paper sensor for specific antigen-antibody detection was demonstrated via

36 ress, cancer-specific distress, and prostate-specific antigen anxiety.

37 e cancers after the introduction of prostate-specific antigen-based screening are now being observed

38 ociated antigen-4) possessing an outer tumor-specific antigen-binding site engineered to shield the i

39 and explored their relation to the prostate-specific antigen blood value, the bone scan index (BSI),

40 ging and unspecific fluctuations in prostate-specific antigen can hamper early diagnosis of castratio

41 The specific antigens captured by this "TCR trap" method wer

42 Overall, this study both identifies specific antigen combinations for high-priority clinical

43 t anti-GRP78 AutoAb levels parallel prostate-specific antigen concentrations in patient-derived serum

44 Men with prostate-specific antigen concentrations up to 15 ng/mL, with no

45 iochemical response as defined by a prostate-specific antigen decline >/= 50% from baseline to at lea

46 At 100 kBq/kg, the duration of prostate-specific antigen decline was less than 4 mo, but if ther

47 30), but not when also adjusted for prostate-specific antigen density (PSAD; HR, 1.85; 95% CI, 0.99 t

48 ccurrence and strong immunogenicity of tumor-specific antigens derived from shared frameshift mutatio

49 Randomisation was stratified by prostate-specific antigen doubling time and baseline use of a bon

50 ion-resistant prostate cancer and a prostate-specific antigen doubling time of 10 months or less.

51 ion-resistant prostate cancer and a prostate-specific antigen doubling time of up to 10 months were r

52 risk for metastatic disease (rapid prostate-specific antigen doubling time or velocity) but otherwis

53 late autoimmune diseases induced with tissue-specific antigens emulsified in adjuvant oils, such as c

54 ansmission SPR measurements of free prostate specific antigen (f-PSA), which is similar in size to BS

55 tify a putative lipoprotein as a potentially specific antigen for B. miyamotoi serodetection.

56 mous cell carcinoma antigen (SCCA) is a good specific antigen for cancer diagnosis specifically for s

57 formed in 36 subjects with a rising prostate-specific antigen for known (n = 15) or suspected (n = 21

58 The most specific antigen for the serodiagnosis of human C abortu

59 e sequential cleavage of the precursor group-specific antigen (Gag) polyprotein by HIV-1 protease.

60 es covering the packaging signal (PS), group-specific antigen (gag), polymerase (pol), and envelope (

61 rade model and clinical parameters (prostate-specific antigen, Gleason score) for pathologic EPE pred

62 received no previous chemotherapy; prostate-specific antigen greater than 5 ng/mL; and a Karnofsky p

63 hological criteria and the analysis of stage-specific antigens (i.e., IGFBP1, PRL).

64 monstrated a sustained reduction in prostate-specific antigen in a patient with CRPC, and another stu

65 trate femtomolar-level detection of prostate-specific antigen in biological fluids, as well as reduce

66 ion of this technology in detecting Prostate Specific Antigen in clinically relevant levels (ng/ml),

67 o known as ETAA16, was identified as a tumor-specific antigen in the Ewing family of tumors.

68 ultaneous detection of antibody binding with specific antigens in arrays containing 96- and 384-spots

69 stochemically by antibodies that target cell-specific antigens in the cytosol or plasma membrane.

70 hat demonstrates for the first time that ASD-specific antigen-induced maternal autoantibodies produce

71 s the MRI-based EPE grading system (prostate-specific antigen, International Society of Urological Pa

72 ng carcinomas, subsequently releasing tumour-specific antigens into the tumour microenvironment highl

73 ng loci until a tailored antibody gene for a specific antigen is satisfactorily generated.

74 However, the identification of cancer-specific antigens is a significant analytical challenge

75 y ex vivo stimulation of primed T cells with specific antigens is described.

76 ell extracts, and TET2 KD increases prostate-specific antigen (KLK3/PSA) expression.

77 ebo (Arm P; n = 433), stratified by prostate-specific antigen (less than 50 ng/mL v 50 ng/mL or more)

78 ical failure was defined as a serum prostate-specific antigen level > 0.2 ng/mL that increased on 2 c

79 nd/or radiation therapy with rising prostate-specific antigen level (median, 2.27 ng/mL; range, 0.2-2

80 lobin level (r = -0.521, P < .001), prostate-specific antigen level (r = 0.556, P < .001), lactate de

81 n tDV and best percentage change in prostate-specific antigen level and circulating tumor cell count

82 gistic regression; correlation with prostate-specific antigen level and circulating tumor cell count

83 The median prostate-specific antigen level at imaging and number of LNM per

84 d Gleason scores of 7-10 and a mean prostate-specific antigen level of 7.8 mug/L (range, 5.4-10.6 mug

85 e cancer, particularly those with a prostate-specific antigen level of less than 10 ng/mL and Gleason

86 hree patients were eligible (median prostate-specific antigen level, 1.9 ng/mL).

87 tate-specific antigen relapse (mean prostate-specific antigen level, 5 ng/mL; range, 0.25-294 ng/mL),

88 Methods: Twenty-one patients (prostate-specific antigen level, 7.4 +/- 6.8 ng/mL) with biochemi

89 Serum prostate-specific antigen level, digital rectal examination findi

90 Hypofractionation, pretreatment prostate-specific antigen level, Gleason score, and clinical tumo

91 astatic findings were compared with prostate-specific antigen level, International Society of Urologi

92 and was associated with increasing prostate-specific antigen level, ISUP grade, and clinical stage.

93 At multivariate analysis, prostate-specific antigen level, primary Gleason grade greater th

94 ADC treatment cycles, or change in prostate-specific antigen level.

95 tal examination results or elevated prostate-specific antigen levels (age groups: 41-50 years, 51-60

96 say was superior to the analysis of prostate-specific antigen levels (area under the curve: 0.94 vers

97 f circulating MDSCs correlates with prostate-specific antigen levels and metastasis in patients with

98 ineate the relationship between the prostate-specific antigen levels and the diffusion parameters as

99 of 140 patients with elevated serum prostate specific antigen levels and/or abnormal digital rectal e

100 by applying mathematical models to prostate-specific antigen levels as the representation of tumour

101 -2, localized prostate cancer, with prostate-specific antigen levels less than 50 ng/mL, and enrolled

102 = 16), after surgery and with serum prostate-specific antigen levels lower than 0.2 ng/mL (n = 13), a

103 radiotracers than fluciclovine for prostate specific antigen levels of 1.0-1.9 ng/mL.

104 n rates even in the presence of low prostate-specific antigen levels.

105 equal to 3 + 4 in men with elevated prostate-specific antigen levels.

106 equal to 3 + 4 in men with elevated prostate-specific antigen levels.

107 te risk prostate cancer (Gleason 7, prostate-specific antigen < 10 ng/mL or Gleason 6, prostate-speci

108 = 7, clinical stage T1b to T3a, and prostate-specific antigen < 30 ng/mL were randomly allocated to n

109 /CT in the detection of early CRPC (prostate-specific antigen <= 3 ng/mL).

110 g detection of high levels of serum prostate-specific antigen, many men are advised to have transrect

111 e, biopsy at 12-month intervals and prostate-specific antigen measurement and digital rectal examinat

112 T cell recognition of specific antigens mediates protection from pathogens and

113 Lake Biwa and speculated that a novel koayu-specific antigen might have been the cause of the condit

114 as 1% +/- 40%, excluding 1 patient (prostate-specific antigen-negative) from the population.

115 curred most often for patients with prostate-specific antigen of 0.5 to less than 2.0 ng/mL (81/147,

116 No prostate-specific antigen or RECIST responses were seen with week

117 1gp49) which binds and cleaves B-band LPS (O-specific antigen, OSA) of Pseudomonas aeruginosa PAO1.

118 tors common across the trials (age, prostate-specific antigen, performance status, alkaline phosphata

119 id cocktail expressing HIV-1 subtype C group-specific antigen, polymerase, and envelope antigen genes

120 mbinant canarypox virus expressing HIV group-specific antigen, polymerase, and envelope genes) follow

121 The radiosensitivity for the prostate-specific antigen-positive patients was determined to be

122 matory response in sarcoidosis is induced by specific antigens, possibly including self-antigens, whi

123 target solid tumors without the necessity of specific antigen presentation on tumors are developed.

124 B7-CD28 co-stimulation and B7 expression by specific antigen-presenting cell (APC) types are require

125 py depends on the robust activation of tumor-specific antigen-presenting cells (APC).

126 owever, gaps in our knowledge as to dormancy-specific antigens prevent a relapse preventing vaccine d

127 ival (cPFS) end point that included prostate-specific antigen progression events.

128 symptomatic, local, or biochemical (prostate-specific antigen) progression.

129 Presence of prostate-specific antigen (proxy for recent sex) and being amenor

130 igible men had an elevated level of prostate-specific antigen (PSA) (>0.2 ng/mL) and high-risk featur

131 All patients had a rising level of prostate-specific antigen (PSA) (range, 0.3-119.0 ng/mL; mean, 10

132 he therapeutic response measured by prostate-specific antigen (PSA) 2 mo after RLT.

133 for PSMA PET with a rising level of prostate-specific antigen (PSA) after RP.

134 erapeutic response as determined by prostate-specific antigen (PSA) and alkaline phosphatase (ALP), a

135 eptor and its target gene products, prostate specific antigen (PSA) and ETS-related gene (ERG).

136 Serum prostate-specific antigen (PSA) and Expanded Prostate Index Compo

137 high Gleason score, clinical stage, prostate-specific antigen (PSA) and extent of disease, as well as

138 ate MR imaging in men with elevated prostate-specific antigen (PSA) and negative transrectal ultrason

139 evaluated the relationship between prostate-specific antigen (PSA) and overall survival in the conte

140 s decorated with antibodies against prostate specific antigen (PSA) and prostate specific membrane an

141 mune complexes of the cancer marker prostate-specific antigen (PSA) are detected and counted by wide-

142 tructure of the glycoproteins, with prostate-specific antigen (PSA) as a model target.

143 roxy-2'-deoxyguanosine (8-OHdG) and prostate specific antigen (PSA) as representatives for small mole

144 f prostate volume, uroflowmetry and prostate specific antigen (PSA) at one, 3 and 6 months and one ye

145 iochemical recurrence stratified by prostate-specific antigen (PSA) at the time of imaging.

146 ned to utilize for the detection of prostate specific antigen (PSA) based on three different generati

147 olicy with salvage radiotherapy for prostate-specific antigen (PSA) biochemical progression.

148 post-prostatectomy surveillance of prostate specific antigen (PSA) can be achieved with a detection

149 ratification systems use presenting prostate-specific antigen (PSA) concentration, biopsy Gleason gra

150 prostatectomy in patients with low prostate-specific antigen (PSA) concentrations (<2.0 ng/mL).

151 ific quality of life, health worry, prostate-specific antigen (PSA) concern, and outlook on life.

152 Men who did not achieve >/= 30% prostate-specific antigen (PSA) decline by cycle 4 (C4) switched

153 A sensitive prostate-specific antigen (PSA) detection method using a visual-r

154 ation-sensitive prostate cancer and prostate-specific antigen (PSA) doubling time (DT) of less than 1

155 sion criterion for this study was a prostate-specific antigen (PSA) doubling time of less than 12 mo

156 We simulate prostate-specific antigen (PSA) dynamics, with enrichment of PCa

157 CT is increasingly used in men with prostate-specific antigen (PSA) failure after radical prostatecto

158 ions of histopathology, imaging, or prostate-specific antigen (PSA) follow up, defined as composite r

159 Surveillance was performed with prostate-specific antigen (PSA) follow-up every 3 months, with re

160 quantitatively precise analysis of prostate-specific antigen (PSA) in 10 min from merely one drop of

161 For the measurements of prostate-specific antigen (PSA) in 50% serum using the proposed m

162 ndothelial growth factor (VEGF) and prostate-specific antigen (PSA) in human serum for early diagnosi

163 bel-free and real-time detection of prostate specific antigen (PSA) in human serum using silicon nano

164 aptasensor to detect the biomarker prostate specific antigen (PSA) in serum.

165 Prostate specific antigen (PSA) is a glycoprotein which has been

166 The diagnostic specificity of prostate specific antigen (PSA) is limited.

167 Prostate specific antigen (PSA) is the common biomarker for prost

168 pore blockade sensing system, where prostate-specific antigen (PSA) is used as a model analyte.

169 Prostate-specific antigen (PSA) is widely used to monitor treatme

170 mine the relationship between serum prostate-specific antigen (PSA) level categories (<5, 5-10, 10-20

171 on therapy (ADT), as reflected by a prostate-specific antigen (PSA) level higher than 4.0 ng/mL after

172 ars), stage cT2a or less, and serum prostate-specific antigen (PSA) level less than 10 ng/mL.

173 ted radiotracers in patients with a prostate-specific antigen (PSA) level less than 2 ng/mL.

174 state cancer in 60% of cases with a prostate-specific antigen (PSA) level of >=0.4 to <0.5, 78% with

175 ge of biochemical recurrence with a prostate-specific antigen (PSA) level of less than 1 ng/mL.

176 The median prostate-specific antigen (PSA) level was 1.2 ng/mL (range, 0.2-2

177 -free survival as determined by the prostate-specific antigen (PSA) level, clinical progression-free

178 tive biopsy findings with increased prostate-specific antigen (PSA) level, or (c) had a prior history

179 rence was correlated with patients' prostate-specific antigen (PSA) level, primary Gleason score, and

180 ent characteristics, including age, prostate-specific antigen (PSA) level, PSA density, race, digital

181 ersistently or recurrently elevated prostate-specific antigen (PSA) level.

182 e blood of 72 asymptomatic men with Prostate-Specific Antigen (PSA) levels < 20 ng ml(-1), of whom 31

183 an imaging protocol based on rising prostate-specific antigen (PSA) levels (mean, 3.43 ng/mL; median,

184 an imaging protocol based on rising prostate-specific antigen (PSA) levels (mean:3.43 ng/mL, median:0

185 of 85%, which increased with higher prostate-specific antigen (PSA) levels (ng/mL): 50% (PSA < 0.5),

186 scan results (P < 0.001) and higher prostate-specific antigen (PSA) levels (P = 0.024) were associate

187 MA I&T PET/CT because of increasing prostate-specific antigen (PSA) levels after radical prostatectom

188 icant proportion of men with rising prostate-specific antigen (PSA) levels after radical prostatectom

189 t statistical model of longitudinal prostate-specific antigen (PSA) levels and risks for biopsy upgra

190 Prostate-specific antigen (PSA) levels have been used for detecti

191 genes associated with pre-operative prostate-specific antigen (PSA) levels in patients.

192 tients with postprostatectomy serum prostate-specific antigen (PSA) levels of at least 0.2 ng/mL and

193 state cancer and rapidly increasing prostate-specific antigen (PSA) levels while taking androgen-depr

194 survival of patients with different prostate-specific antigen (PSA) levels, Gleason scores, marital s

195 in Solid Tumors 1.1), a decrease in prostate-specific antigen (PSA) of 50% or more (PSA50) from basel

196 red eighteen patients with a median prostate-specific antigen (PSA) of 6.4 ng/mL (range, 2.2-158.4 ng

197 s in a selected patient cohort with prostate-specific antigen (PSA) persistence after salvage lymph n

198 tive radiotherapy, 51% (88/172) for prostate-specific antigen (PSA) persistence, and 36% (62/172) for

199 week 13 (PET2), and at the time of prostate-specific antigen (PSA) progression, standard radiographi

200 Prostate-specific antigen (PSA) progression-free survival (PFS) a

201 nued until radiologic, clinical, or prostate-specific antigen (PSA) progression; otherwise, treatment

202 Patients were stratified as prostate specific antigen (PSA) progressive versus responsive bas

203 on strongly associates with reduced prostate-specific antigen (PSA) recurrence-free survival.

204 investigators) and locally assessed prostate-specific antigen (PSA) response (>= 50% decrease from ba

205 Endpoints included prostate-specific antigen (PSA) response (Prostate Cancer Working

206 se was 11.55 Gy and correlated with prostate-specific antigen (PSA) response at 12 wk.

207 13 circulating tumor cell (CTC) and prostate-specific antigen (PSA) response end points in five prosp

208 Primary objectives were: confirmed prostate-specific antigen (PSA) response rate (RR) and whether ET

209 phic progression-free survival, and prostate-specific antigen (PSA) response rate.

210 GBq); afterward, safety lab tests, prostate-specific antigen (PSA) response, and clinical findings w

211 tive disease associated with better prostate-specific antigen (PSA) responses (100% vs. 54%, P = 0.03

212 We examined >/= 50% prostate-specific antigen (PSA) responses, PSA progression-free s

213 on on enzalutamide with a continued prostate-specific antigen (PSA) rise after enzalutamide treatment

214 The development of the prostate specific antigen (PSA) test, and a continuing decrease i

215 fication to identify those for whom prostate-specific antigen (PSA) testing is likely to be most valu

216 Prostate specific antigen (PSA) tests and digital rectal exams ca

217 ood and Drug Administration) is the prostate specific antigen (PSA) that is detected by conventional

218 ngle molecules of the cancer marker prostate specific antigen (PSA) using photon-upconversion nanopar

219 The median prostate-specific antigen (PSA) value was 1.0 ng/mL (mean, 4.7 ng

220 Interestingly, on considering prostate-specific antigen (PSA) value, (64)CuCl2 PET/CT had a hig

221 n of recurrent disease at low serum prostate specific antigen (PSA) values below 0.5 ng/mL compared w

222 o standard-of-care imaging at serum prostate-specific antigen (PSA) values low enough to affect targe

223 rd, data were compared with current prostate-specific antigen (PSA) values, Gleason score (GS), and d

224 ns challenging in patients with low prostate-specific antigen (PSA) values.

225 Prostate-specific antigen (PSA) was measured for response assessm

226 Serial prostate-specific antigen (PSA) was obtained for PSA response ass

227 Here, prostate-specific antigen (PSA) was selected as a template model.

228 Testosterone and prostate-specific antigen (PSA) were measured at baseline and all

229 low rate, postvoid residual volume, prostate-specific antigen (PSA), and prostate volume were assesse

230 tients with renewed increase in the prostate-specific antigen (PSA), commonly referred to as biochemi

231 omes was constructed combining age, prostate-specific antigen (PSA), histological grade, biopsy core

232 ription of AR target genes, such as prostate-specific antigen (PSA), is also lowered in the HSP90 Thr

233 led for PSMA RLT were evaluated for prostate-specific antigen (PSA), lactate dehydrogenase (LDH), and

234 Prostate cancer biomarkers prostate specific antigen (PSA), vascular endothelial growth fact

235 e implemented for glycoprofiling of prostate specific antigen (PSA), what can be applied for better p

236 ent-free survival (EFS), an earlier prostate-specific antigen (PSA)-based composite end point, may fu

237 individualised decision-making for prostate-specific antigen (PSA)-based screening in men aged 55-69

238 The goal of prostate-specific antigen (PSA)-based screening is to identify ea

239 The prostate-specific antigen (PSA)-stratified detection rate of (18)

240 a prostate cancer's biomarker, the prostate-specific antigen (PSA).

241 ein-related peptidase 3 (KLK3), aka prostate-specific antigen (PSA).

242 tes: alkaline phosphatase (ALP) and prostate-specific antigen (PSA).

243 able for the primary end point of a prostate-specific antigen (PSA)50 response (PSA decline >=50% at

244 thin films as transducers to detect prostate specific antigens (PSA) in a physiological buffer soluti

245 of either biochemical progression (prostate-specific antigen [PSA] >=0.4 ng/mL and rising after comp

246 sk (clinical stage cT1 to cT2bN0M0, prostate-specific antigen [PSA] <=20 ng/mL, and Grade Group 1-2)

247 (T1 to 2a, Gleason score </= 6, and prostate-specific antigen [PSA] 10.1 to 20 ng/mL; T2b to 2c, Glea

248 formance of 4 candidate surrogates (prostate-specific antigen [PSA] failure, PSA nadir >0.5 ng/mL, PS

249 P; that is, persistently measurable prostate-specific antigen [PSA] values after robot-assisted lapar

250 al stage, T1c; Gleason score, </=6; prostate-specific antigen [PSA], <10 ng/mL; PSA density <0.15 ng/

251 intermediate-risk prostate cancer (prostate-specific antigen [PSA], <=15 ng/mL; Gleason score, <=3 +

252 nted biochemical recurrence (median prostate-specific antigen [PSA], 2.5 ng/mL; range, 0.21-35.5 ng/m

253 ucing alphabeta T cell clones with psoriasis-specific antigen receptors exist in clinically resolved

254 at delivery of liposomes containing both the specific antigen recognized by the mast cell-bound IgE a

255 correlated with Gleason scores and prostate-specific antigen recurrence.

256 ean age, 68 y; range, 44-87 y) with prostate-specific antigen relapse (mean prostate-specific antigen

257 The primary endpoint was a prostate-specific antigen response in relation to baseline neuroe

258 ; 95% CI, 0.40 to 0.68; P<0.001), a prostate-specific antigen response occurred in 35.7% and 13.5% of

259 le response, mainly as defined by a prostate-specific antigen response of more than 50%, comparable t

260 xploratory analyses showed a higher prostate-specific antigen response rate with ipilimumab (23%) tha

261 es in progression-free survival and prostate-specific antigen response rates suggest antitumor activi

262 The initial prostate-specific antigen response showed no correlation with tre

263 every 2 wk by laboratory tests, the prostate-specific antigen response was checked every 4 wk, and ot

264 -positive mCRPC had fewer confirmed prostate-specific antigen responses (0% to 11%) or soft tissue re

265 This enrichment of specific antigen responses for fucosylated bisecting gly

266 Prostate-specific antigen responses to ipilimumab were also assoc

267 Overall survival (OS) and prostate-specific antigen responses were secondary end points.

268 BCR was defined as 2 consecutive prostate-specific antigen rises of at least 0.2 ng/mL.

269 Studies demonstrate that use of prostate-specific antigen screening decreased significantly follo

270 rce (USPSTF) recommendation against prostate-specific antigen screening in 2012.

271 ion against routine population-wide prostate-specific antigen screening.

272 the AR-responsive gene that encodes prostate specific antigen, shows the greatest variability in expr

273 esponse, whereas patient 1 achieved prostate-specific antigen stabilization after 3 therapy cycles.

274 This is due in part to a lack of specific antigen targets, poor trafficking and infiltrat

275 Prostate-specific antigen testing every 4 to 6 months is reasonab

276 repair mechanisms and the induction of tumor-specific antigens that can be targeted.

277 cells displayed enhanced expression of stage-specific antigens that extravillous CTBs normally upregu

278 Lysis of tumour cells releases tumour-specific antigens that trigger both the innate and adapt

279 was shown to supress expression of prostate specific antigen, the cardinal clinical biomarker of pro

280 the type as well as level of expressed tumor-specific antigens, thereby presenting methods for select

281 of biomaterial scaffolds loaded with disease-specific antigens to identify and study rare, therapeuti

282 tic cells and prevents presentation of tumor-specific antigens to other immune cells.

283 Re-activation and clonal expansion of tumor-specific antigen (TSA)-reactive T cells are critical to

284 low-abundance MHC I peptides including tumor-specific antigens (TSAs) and minor histocompatibility an

285 The study of tumour-specific antigens (TSAs) as targets for antitumour thera

286 l self-antigen compartment, including tissue-specific antigens (TSAs).

287 l) and tumor characteristics (serum prostate-specific antigen, tumor grade and clinical stage) and by

288 ns limited by the rarity of targetable tumor-specific antigens, tumor-mediated immune suppression, an

289 %) demonstrated a >= 50% decline in prostate-specific antigen; two (6%) of 36 with measurable disease

290 Men with high serum prostate specific antigen usually undergo transrectal ultrasound-

291 rrelations were found between serum prostate-specific antigen value and both PSMA-TV (r = 0.72, P < 0

292 The patients had a median prescan prostate-specific antigen value of 12.2 ng/mL (range, 1.2-81.6 ng

293 8 (standard deviation); the median prostate-specific antigen value was 6.3 ng/mL.

294 ts with prostate cancer BCR (median prostate-specific antigen value, 1.7 ng/mL; range, 0.05-202 ng/mL

295 Patients with low prostate-specific antigen values (<0.5 ng/mL) also demonstrated p

296 0.74, respectively, P < 0.001) and prostate-specific antigen values (r = 0.57 and 0.54, respectively

297 ad undergone PSMA PET for CRPC, had prostate-specific antigen values of at least 1 ng/mL, and had und

298 Median prostate-specific antigen was 15.1 ng/mL; 53% had a Gleason score

299 erspective explore the detection of prostate-specific antigen which enables a comparison between stra

300 l outputs, the PT-Disk can quantify prostate specific antigen with limits of detection of 1.4-2.8 ng